دورية أكاديمية

Multi-Disciplinary Care of Hilar Cholangiocarcinoma: Review of Guidelines and Recent Advancements.

التفاصيل البيبلوغرافية
العنوان: Multi-Disciplinary Care of Hilar Cholangiocarcinoma: Review of Guidelines and Recent Advancements.
المؤلفون: Padmanaban, Vennila, Ruff, Samantha M., Pawlik, Timothy M.
المصدر: Cancers; Jan2024, Vol. 16 Issue 1, p30, 14p
مصطلحات موضوعية: BILE duct tumors, BILE duct adenocarcinoma, MEDICAL protocols, ANTIMETABOLITES, ADJUVANT treatment of cancer, CHEMORADIOTHERAPY, HEALTH care teams, COMPUTED tomography, COMBINED modality therapy, BILE ducts, PROGRESSION-free survival
مستخلص: Simple Summary: Upfront surgery with adjuvant capecitabine is the only curative treatment for hilar cholangiocarcinoma. Unfortunately, most patients do not present with resectable disease and are treated with a combination of locoregional therapy and systemic therapy. This review will summarize existing literature and ongoing clinical trials focused on the multidisciplinary care of hilar cholangiocarcinoma. Cholangiocarcinoma (CCA) is a rare malignancy of the intrahepatic and extrahepatic biliary ducts. CCA is primarily defined by its anatomic location: intrahepatic cholangiocarcinoma versus extrahepatic cholangiocarcinoma. Hilar cholangiocarcinoma (HC) is a subtype of extrahepatic cholangiocarcinoma that arises from the common hepatic bile duct and can extend to the right and/or left hepatic bile ducts. Upfront surgery with adjuvant capecitabine is the standard of care for patients who present with early disease and the only curative therapy. Unfortunately, most patients present with locally advanced or metastatic disease and must rely on systemic therapy as their primary treatment. However, even with current systemic therapy, survival is still poor. As such, research is focused on developing targeted therapies and multimodal strategies to improve overall prognosis. This review discusses the work-up and management of HC focused on the most up-to-date literature and ongoing clinical trials. [ABSTRACT FROM AUTHOR]
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:20726694
DOI:10.3390/cancers16010030